pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
By Douglas E. V. Pires, Tom L. Blundell, David B. Ascher. Journal of Medicinal Chemistry, 2015
4,911 citations recorded by the source corpus.
Drug development has a high attrition rate, with poor pharmacokinetic and safety properties a significant hurdle. Computational approaches may help minimize these risks. We have developed a novel approach (pkCSM) which uses graph-based signatures to develop predictive models of central ADMET properties for drug development. pkCSM performs as well or better than current methods. A freely accessible web server (http://structure.bioc.cam.ac.uk/pkcsm), which retains no information submitted to it, provides an integrated platform to rapidly evaluate pharmacokinetic and toxicity properties.
Subfields: Computational Theory and Mathematics, Materials Chemistry, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/3a01d62b9e180ee3d2dfdec3910a60aead2de1f9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- Antoine Daina
- Vincent Zoete
- Olivier Michielin
- Carlos H. M. Rodrigues
- Douglas E. V. Pires
- David B. Ascher
- Yoochan Myung
- Xianhuan Shen
In Materials Chemistry
- Antoine Daina
- Vincent Zoete
- Olivier Michielin
- Douglas E. V. Pires
- Carlos H. M. Rodrigues
- David B. Ascher
- Yoochan Myung
- Dongsheng Cao
In Organic Chemistry
- Carlos H. M. Rodrigues
- Vincent Zoete
- Olivier Michielin
- Antoine Daina
- Douglas E. V. Pires
- David B. Ascher
Citations in the corpus
- Computational Approaches in Preclinical Studies on Drug Discovery and Development (2020, background): “…intestinal absorption rate, oral bioavailability, blood-brain barrier permeation rate, Caco-2 permeability, human intestinal absorption, drug interactions, P-glycoprotein, plasma protein binding rate, CYP metabolic enzymes, and kidney clearance (Pires et al., 2015; Dong et al., 2018) ( Figure 5 ).”
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules (2017, positive): “Compared to the state-of-the art of free web-based tools for ADME and pharmacokinetics (e.g. pk-CSM 14 and admetSAR 15 ) and apart from unique access to proficient methods (e.g. iLOGP 16 or the BOILED-Egg 17 ), SwissADME strong points are, non-exhaustively: different input methods, computation for…”
- mCSM-PPI2: predicting the effects of mutations on protein–protein interactions (2019, methodology): “This approach models both the geometry and physicochemical properties of the interactions and architecture of wild-type structure and has been widely applied to the study of small molecule and protein structure (20,26–34 , 42”
- DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations (2020, background): “Our in-house graph-based signatures approach to represent molecular structures 35,59 – 61 has proven to be successful for a range of applications toward the study of protein structure and changes carried out by missense mutations, 35,37,41 – 48 including phenotypic changes.”
- ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database (2018, background): “Moreover, most of existing computational tools are individual models which focus on specific ADMET properties and few can evaluate different ADMET properties simultaneously due to the limited data size and meth-ods [12–14].”